Clinicopathological Features of DLL3 Expression and T‐Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab
Large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive lung neuroendocrine neoplasm with poor prognosis. Recently, DLL3‐targeted bispecific T‐cell engagers (BiTEs) have shown promising efficacy in small cell lung cancer, and clinical trials are ongoing in LCNEC. This study evaluated DLL3 expression and CD...